Market Newsdesk

MONTREAL, May 04, 2021 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has timely filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19 treatment under development. Sunshine had originally filed a provisional patent application covering the COVID-19 treatment on May 22, 2020. This priority date has been maintained in the newly filed PCT application.

In addition to the original subject matter pertaining to inhibitors of the Main Coronavirus protease, Mpro, the PCT application contains data and extends coverage to include the Papain-Like Coronavirus protease, PLpro. The latter is an important antiviral target as it is involved in suppression of the host immune system thereby leading to more severe illness.

The etiologic agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral polyproteins, pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease, Mpro (also called 3CLpro and nsp5). In addition to Mpro, a second cysteine protease, called PLpro, is generated. Mpro and PLpro cleave the viral polyproteins at a number of specific sites thereby generating several mature proteins essential for viral replication. PLpro also cleaves certain host cell proteins resulting in suppression of the immune system and elevated morbidity. Because of their functional indispensability in viral replication, Mpro and PLpro are attractive targets for the development of anti-COVID-19 therapy.

In collaboration with the University of Georgia, College of Pharmacy, Sunshine has been pursuing the development of several PLpro inhibitors and currently has two drug candidates of such under evaluation in hACE2-transgenic mice. Sunshine anticipates that the COVID-19 treatment under development will also be effective against the variants of concern.

“The PCT represents a major milestone for our COVID-19 treatment project, as it strengthens our intellectual property position and allows us to file patents on a worldwide basis going forward,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.2 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting.

About Adva-27a Anticancer Drug

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact:

Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

Signing the
Lease Agreement for
Their
World-Class Manufacturing Facility

TORONTO, May 04, 2021 (GLOBE NEWSWIRE) — Worksport Ltd (OTC: WKSP) (or the “Company”) is excited to update its investors, shareholders, and supporters that it officially signed a lease agreement for its new Canadian manufacturing facility. This memorializes a deal which also creates a valuable relationship with the property’s ownership, a fully integrated, Tier-one, OEM automotive manufacturer and supplier. Along with being the property owner, management may be advising Worksport leadership at the beginning, fostering a strong working relationship with the Company, helping to develop Worksport’s manufacturing footprint in Canada and position the Company to effectively manage expected growth. “My team and I are very excited for the opportunity to work with such an established business in the automotive manufacturing sector and very much look forward to what the future holds,” states Worksport CEO Steven Rossi.

The facility – located in Mississauga, Ontario, Canada, is in a manufacturing hub just outside of Toronto, minutes from Person International Airport – and will be upgraded at no further expense to Worksport. As a result, Worksport’s new world-class facility could be move-in ready within just a couple months. Another major benefit of this business partnership will give the Company the ability to grow into the space. At first, Worksport will utilize under half of the available space, taking more as the Company expands and grows, being a huge cost-savings benefit to Worksport.

It is worth noting that this manufacturing facility will far exceed the needs for any equipment the Company could require to meet its expected goals. As an added benefit, the operating space comes already equipped with stamping presses that could be utilized in the production process, with minimal capital expenditure. Additionally, the Company has begun to purchase advanced tools to aid in further development of its current and upcoming product lines, from technologically advanced 3D scanners to 3D printers allowing for rapid prototyping to get new products to market faster.

This new facility will be where the forthcoming TerraVis^™ is proposed to be assembled and enhanced, with plans for close partner collaboration aiding in meticulous oversight. Worksport management is also moving ahead with new projects. Along with the Company setting up a best-in-class R&D departments, Worksport is working on developing new technologies, focussed on creating even more value for the EV & Sustainable Energy industries. Management will disclose new projects in the near future.

To stay up-to-date on all the latest Worksport news… investors, shareholders, and supporters are encouraged to follow the company’s social media accounts on Twitter, Facebook, LinkedIn, and Instagram, as well as sign up for the company’s newsletters at www.worksport.com and www.goterravis.com. Worksport will continue to update investors, shareholders, and supporters to maintain the highest level of disclosure and information dissemination as Worksport continues to grow and develop at a very rapid pace.

About Worksport Ltd.

Worksport Ltd. (currently OTCQB: WKSP) develops and manufactures high quality, modular, attractively priced tonneau covers and solar-powered systems for light-duty trucks such as the Sierra, Silverado, Canyon, RAM, Ford F-Series, et al. as well as consumer adventures & emergency/ disaster-recovery purposes, where portable energy is a necessity. The modular, redefining Worksport TerraVis^™ tonneau cover system is being mindfully designed for the jobsite contractor and off-road, light-duty trucker – for work and play – to sustainably supply extra energy for those additional miles. Its allied TerraVis COR^™ mobile energy storage system (ESS), expected to launch by end of 2021, will be another redefining product targeted for vacationers, second-home owners, and campers. Plans are also being constructed to address the dire adoption & scaling needs of the EV markets with grid micro-charging stations to provide convenience and efficiency in recharging to smaller form-factor EVs. For more information, please visit www.worksport.com and www.goterravis.com.

Connect with Worksport: 

LinkedIn

Facebook

Twitter

Instagram

For
additional
information
,
please contact:

Faran Ali

Business Development Manager
Worksport Ltd
T: 1-(888) 506-2013
E: [email protected]

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of the Company concerning its business strategy, an up listing to a national exchange, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company’s current expectations and
assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results. No Stock Exchange or Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

WATERLOO, ON, May 04, 2021 (GLOBE NEWSWIRE) — Auvik, an award-winning provider of cloud-based network management software, today released a commissioned study conducted by Forrester Consulting that quantifies the total economic impact and benefits of Auvik’s solution. In the study, Forrester found that enterprises implementing Auvik obtained a return on investment (ROI) of 173% over three years. 

Auvik is cloud-based network management software that can provide actionable intelligence on a network in under 30 minutes in a simple, intuitive interface, designed to scale with a business. Through a single dashboard, it offers automated network discovery, inventory, and documentation; simplified network performance monitoring and troubleshooting; and automated configuration backup and recovery—Auvik converts dozens of time-consuming tasks into simple, automated steps. With support for over 15,000+ devices from over 700 vendors, Auvik is the present and future of network monitoring and management, accelerating an IT team’s efficiency and capacity while protecting the business from network risk. 

“As we continue to shift to a remote-first world, the importance of networks and the critical function they play in our daily lives is increasingly evident,” said Marc Morin, CEO of Auvik Networks. “We believe this Forrester study affirms how Auvik improves IT team efficiency with a consolidated automated system, offering great network performance visibility, significant efficiencies in issue detection and resolution, and deep network traffic insights.” 

Forrester interviewed Auvik customers to understand the benefits, costs, and risks associated with using the Auvik system. The firm then aggregated the results into a single composite organization to form a model for prospective customers to evaluate the potential quantifiable impact of deploying Auvik in their organization. 

The study’s results revealed significant cost savings and business benefits for IT organizations that have implemented Auvik. Over three years, Forrester’s analysis revealed an enterprise would realize significant cost savings, including: 

• The ability to quickly remedy issues, automate configuration backups, and improve access to network documentation allows for over $1M in network monitoring time savings and reduces the network monitoring time by two hours per network per month.
• Combining a mix of disparate network management tools into one system avoids $600K in legacy license costs.
• Access to automated, real-time information in one central platform eliminates clunky, on-premise and manual tasks by network specialists, allowing network managers to redeploy staff to higher-level tasks and gain $567K in improved efficiencies.

According to an Auvik customer interviewed for the study, a chief technology officer at an IT services management company, “Auvik has a great ability to map the networks and automatically back up the configurations. It helps us tremendously from a troubleshooting standpoint by pinpointing where to look first.” 

Another interviewed customer, a director of managed services at an MSP, highlighted the efficiencies gained in task execution, “Auvik allows my first- and second- level technicians to troubleshoot issues rather than having to immediately escalate them to my level-three or level-four guys.”

To download The Total Economic Impact of Auvik’s Network Management Solution, visit auvik.com/total-economic-impact.

About Auvik Networks

Auvik’s cloud-based network management software keeps IT networks around the world running optimally. By automating and simplifying network management, Auvik helps rocket an IT team’s efficiency and capacity, while protecting the business from network risk. Auvik is one of the fastest growing North American technology companies, and is winner of the Deloitte Technology Fast 50, Deloitte Fast 500, and recognized as the #1 ranked Canadian company in the FT Americas’ Fastest Growing Companies 2020. Visit www.auvik.com or follow @AuvikNetworks on Twitter. Auvik is a registered trademark of Auvik Networks Inc.